BTP to expand into drugs
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.BTP, Britain's fifth-biggest chemical company, said it will buy France's Hexachimie SAS, a unit of the Bristol-Myers Squibb Co, for $87.5m in cash in a move to expand its sales to drug companies.
BTP, which makes base chemicals for Pfizer Inc.'s new impotence drug Viagra and other chemicals, said Hexachimie has "unique expertise'' in making base, or "intermediate'' chemicals for agrochemicals and pharmaceuticals. A third of Hexachimie's sales are to Bristol-Myers, a major drug company and the world's biggest maker of cancer drugs.
Hexachimie reported sales of $42.7m in the year to Dec. 31, 1997, with operating profit of $8.6m. Net assets were $45.8m.
Led by Chief Executive Steve Hannam, BTP has undergone a major drive into higher-margin sectors of the specialty chemical business in recent years.
BTP shares closed down 1p at 508p.
- Bloomberg
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments